MedTrace Logo

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

NCT03913741 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-06-23

No results posted yet for this study

Summary

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies

Conditions

Interventions

DRUG

tisotumab vedotin

Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial

Sponsors & Collaborators

  • Seagen Inc.

    collaborator INDUSTRY

  • Genmab

    lead INDUSTRY

Principal Investigators

  • Keiichi Fujiwara, Professor · Saitama Medical University International Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-27
Primary Completion
2020-08-14
Completion
2021-10-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03913741 on ClinicalTrials.gov